STAT3β在急性髓系白血病中发挥抑癌作用
研究分析AML患者STAT3β/α mRNA比值,发现较高比值与良好预后和总生存期延长相关;在PTEN和MLL-AF9依赖的AML小鼠模型中,转基因表达Stat3β可减缓疾病进展并延长生存,其抑癌功能依赖于肿瘤内在少数基因的调控。
要点
- AML患者中较高的STAT3β/α mRNA比值与良好预后和总生存期增加相关。
- 在PTEN和MLL-AF9依赖的AML小鼠模型中,转基因Stat3β表达减缓疾病进展并延长生存。
- STAT3β的抗肿瘤功能依赖于肿瘤内在少数显著上调和下调基因的调控。
核心结论
- STAT3β在急性髓系白血病中发挥必要的肿瘤抑制角色。
研究设计与样本
- 分析AML患者STAT3β/α mRNA表达比值,并构建允许平衡表达Stat3β的转基因小鼠,在PTEN和MLL-AF9依赖的AML小鼠模型中研究其功能。
主要发现
- AML患者中较高的STAT3β/α mRNA比值与良好预后和总生存期增加相关。
- 转基因Stat3β表达在PTEN和MLL-AF9依赖的AML小鼠模型中导致疾病进展减缓并延长生存。
- STAT3β的抗肿瘤功能依赖于肿瘤内在少数显著上调和下调基因的调控,这些基因通过RNA测序鉴定。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Signal transducer and activator of transcription 3 (STAT3) exists in 2 alternatively spliced isoforms, STAT3α and STAT3β. Although truncated STAT3β was originally postulated to act as a dominant-negative form of STAT3α, it has been shown to have various STAT3α-independent regulatory functions. Recently, STAT3β gained attention as a powerful antitumorigenic molecule in cancer. Deregulated STAT3 signaling is often found in acute myeloid leukemia (AML); however, the role of STAT3β in AML remains elusive. Therefore, we analyzed the STAT3β/α messenger RNA (mRNA) expression ratio in AML patients, where we observed that a higher STAT3β/α mRNA ratio correlated with a favorable prognosis and increased overall survival. To gain better understanding of the function of STAT3β in AML, we engineered a transgenic mouse allowing for balanced Stat3β expression. Transgenic Stat3β expression resulted in decelerated disease progression and extended survival in PTEN- and MLL-AF9-dependent AML mouse models. Our findings further suggest that the antitumorigenic function of STAT3β depends on the tumor-intrinsic regulation of a small set of significantly up- and downregulated genes, identified via RNA sequencing. In conclusion, we demonstrate that STAT3β plays an essential tumor-suppressive role in AML.
引用
- Aigner P, Mizutani T, Horvath J, et al. STAT3β is a tumor suppressor in acute myeloid leukemia. Blood Adv. 2019. PMID: 31270081. doi:10.1182/bloodadvances.2018026385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。